SynthesisJournal of the American Academy of Dermatology2011
A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus.
Synthesis in Journal of the American Academy of Dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- Pooled it
- Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.The British journal of dermatology · 2020Trial
- Correlation between polymorphisms of the NR3C1 gene and glucocorticoid effectiveness in patients with pemphigus vulgaris.Scientific reports · 2017Trial
- A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.The British journal of dermatology · 2015Trial
- Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies.The Journal of biological chemistry · 2013Trial
- Efficacy and tolerability of rituximab in patients with pemphigus foliaceus: a single-centre retrospective cohort study.Skin health and disease · 2026Article
- Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Senear-Usher Syndrome or Coexistence of SLE with Pemphigus Vulgaris-A Case Report with Literature Review.Journal of clinical medicine · 2025Review
- Rituximab-induced serum sickness in immunobullous disorders: A case series.Clinical case reports · 2024Article
- Senear-Usher syndrome in a 5-year-old girl.Postepy dermatologii i alergologii · 2024Article
- Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa.The British journal of dermatology · 2022Article
- Effect of NUDT15 polymorphisms on early hematological safety of low-dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study.The Journal of dermatology · 2022Article
- A Case of Severe Bullous Dermatitis With Mixed Bullous Pemphigoid and Pemphigus Vulgaris Cutaneous Manifestations.Cureus · 2021Article
- Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study.Acta dermato-venereologica · 2021Article
- Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.Dermatologic therapy · 2021Review
- Assessing the compliance of systematic review articles published in leading dermatology journals with the PRISMA statement guidelines: A systematic review.JAAD international · 2020Review
- A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study.Dermatology and therapy · 2020Article
- Pemphigus vulgaris.Anais brasileiros de dermatologia · 2019Article
- Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- [Therapy of pemphigus].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundA range of interventions has been described for the treatment of pemphigus; however, the optimal therapeutic strategy has not been established.
objectiveWe sought to evaluate the safety and efficacy of interventions for pemphigus vulgaris and pemphigus foliaceus.
methodsWe undertook a systematic review and meta-analysis according to the methodology of the Cochrane Collaboration. We selected randomized controlled trials including participants with the diagnosis of pemphigus vulgaris or pemphigus foliaceus confirmed with clinical, histopathological, and immunofluorescence criteria. All interventions were considered. Primary outcomes studied were remission and mortality. Secondary outcomes included disease control, relapse, pemphigus severity score, time to disease control, cumulative glucocorticoid dose, serum antibody titers, adverse events, and quality of life.
resultsEleven studies with a total of 404 participants were identified. Interventions assessed included prednisolone dose regimen, pulsed dexamethasone, azathioprine, cyclophosphamide, cyclosporine, dapsone, mycophenolate, plasma exchange, topical epidermal growth factor, and traditional Chinese medicine. We found some interventions to be superior for certain outcomes, although we were unable to conclude which treatments are superior overall. LIMITATIONS: Many interventions for pemphigus have not been evaluated in controlled trials. All studies were insufficiently powered to establish definitive results.
conclusionsThere is inadequate evidence available at present to ascertain the optimal therapy for pemphigus vulgaris and pemphigus foliaceus. Further randomized controlled trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.